Pilot Analysis of Late Conversion to Belatacept in Kidney Transplant Recipients for Biopsy-Proven Chronic Tacrolimus Toxicity

Table 3

eGFR mL/min/1.73 m² before conversion, at conversion (month 0), and after conversion with associated allograft biopsy findings.

	eGFR								CADI score	% A	% CI	% CT
	Month; −18	Month; −12	Month; −6	Month; 0	Month; 3	Month; 6	Month; 12	Month; 24
Patient 1	22	20	21	14	15	11	11	--	3	25%	20%	20%
Patient 2	39	46	43	38	40	40	50	37	6	20%	10%	10%
Patient 3	50	38	40	38	46	50	50	55	8	53%	40%	40%
Patient 4	47	47	43	46	43	38	34	28	5	60%	15%	15%
Patient 5	29	28	33	35	37	32	31	---	6	80%	20%	20%
Patient 6	47	40	34	31	37	37	34	41	9	31%	30%	30%
Patient 7	45	30	28	28	31	31	34	37	6	58%	20%	15%
Mean ± SD
value	---	---	---	---	0.09	0.63	0.57	0.92

Paired two-tailed -test, comparing eGFR at conversion with eGFR at subsequent months. CADI: chronic allograft damage index; A: arteriolosclerosis; CI: interstitial fibrosis; CT: tubular atrophy; SD: standard deviation. Biopsy data was collected before conversion in all cases (see text). Note. Month 24 data was not available for patient 5, who is deceased. Patient 1 suffered allograft loss after month 12 and was retransplanted.